Get started
Author

Mohamed Javad Wahadat

Observed names: M Javad Wahadat, M. J. Wahadat, M. Javad Wahadat, M.J. Wahadat, Wahadat M Javad, Wahadat, M. J.
ORCID: 0000-0003-3961-1274
Observed ORCID: 0000-0003-3961-1274
OpenAlex ID: A5049290658
Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors?
2018 · M. Javad Wahadat, Iris L. A. Bodewes, et al. · Arthritis Research & Therapy · 70
PDF
LLDAS is an attainable treat-to-target goal in childhood-onset SLE
2021 · Mohamed Javad Wahadat, Lotte van den Berg, et al. · Lupus Science & Medicine · 35
PDF
Trained Immunity in Primary Sjögren’s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype
2022 · Erika Huijser, Cornelia G. van Helden-Meeuwsen, et al. · Frontiers in Immunology · 25
PDF
Dysregulated endothelial cell markers in systemic lupus erythematosus: a systematic review and meta-analysis
2023 · S. C. Bergkamp, M. J. Wahadat, et al. · Journal of Inflammation · 21
PDF
Serum IFNα2 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort
2022 · M Javad Wahadat, Hongchao Qi, et al. · Lara D. Veeken · 20
PDF
MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis
2019 · Erika Huijser, Cornelia G van Helden-Meeuwsen, et al. · Lara D. Veeken · 19
PDF
Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study
2022 · M Javad Wahadat, Dieneke Schonenberg-Meinema, et al. · Lara D. Veeken · 17
PDF
Targeted multiomics in childhood-onset SLE reveal distinct biological phenotypes associated with disease activity: results from an explorative study
2023 · Mohamed Javad Wahadat, Sander J van Tilburg, et al. · Lupus Science & Medicine · 10
PDF
Alternative exon usage in TRIM21 determines the antigenicity of Ro52/TRIM21 in systemic lupus erythematosus
2022 · Eduardo Gomez-Bañuelos, M. Javad Wahadat, et al. · JCI Insight · 10
PDF
Extranodal marginal zone lymphoma clonotypes are detectable prior to eMZL diagnosis in tissue biopsies and peripheral blood of Sjögren’s syndrome patients through immunogenetics
2023 · P. Martijn Kolijn, Erika Huijser, et al. · Frontiers in Oncology · 9
Learning from serum markers reflecting endothelial activation: longitudinal data in childhood-onset systemic lupus erythematosus
2024 · Sandy C Bergkamp, Nick D Bergkamp, et al. · Lupus Science & Medicine · 7
PDF
Anti-mitochondrial antibodies as markers of disease activity in childhood-onset systemic lupus erythematosus: a longitudinal cohort study
2025 · Marina Barguil Macêdo, Mohamed Javad Wahadat, et al. · Lara D. Veeken · 3
Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro : a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseases
2025 · Albin Björk, Mohamed Javad Wahadat, et al. · RMD Open · 3
PDF
Gene Signature Fingerprints Stratify SLE Patients in Groups with Similar Biological Disease Profiles: A Multicenter Longitudinal Study
2021 · M.J. Wahadat, D. Schonenberg-Meinema, et al. · SSRN Electronic Journal · 2
Thu0240 Gene Expression Signatures Are Related to Specific Subsets of Patients With Systemic Lupus Erythematosus
2019 · M. Javad Wahadat, Noortje Groot, et al. · Annals of the Rheumatic Diseases · 2
PDF
Ab0081 Endothelial Markers With Dysregulation in Systemic Lupus Erythematosus: a Systematic Literature Review
2021 · S. Bergkamp, M.J. Wahadat, et al. · Annals of the Rheumatic Diseases · 1
PDF
Pos0134 Learning From Longitudinal Data in Childhood Onset Systemic Lupus Erythematosus: Which Biomarkers Have Predictive Value for Endothelial Involvement?
2023 · S. Bergkamp, N. Bergkamp, et al. · Annals of the Rheumatic Diseases
PDF
Pos1428 Amlexanox Inhibits Production of Type I Interferon and Suppresses B Cell Differentiation and Immunoglobulin Production in Vitro: a Potential Novel Therapeutic Option for Sle
2023 · A. Björk, M. J. Wahadat, et al.
PDF
Additional file 4 of Dysregulated endothelial cell markers in systemic lupus erythematosus: a systematic review and meta-analysis
2023 · Bergkamp, S. C., Wahadat, M. J., et al. · Figshare
Additional file 3 of Dysregulated endothelial cell markers in systemic lupus erythematosus: a systematic review and meta-analysis
2023 · Bergkamp, S. C., Wahadat, M. J., et al. · Figshare
PO.3.67 Measuring IFNA2 levels by a single-molecule array in clinical practice of childhood-onset sle patients does matter; results from a single center longitudinal study
2022 · Marleen Verkaaik, Wahadat M Javad, et al.
PDF
Pos0178 Gene Signature Fingerprints Divide Sle Patients in Subgroups With Comparable Biological Disease Profiles: a Multicentre Longitudinal Study
2021 · M.J. Wahadat, C.G. Van Helden-Meeuwsen, et al. · Annals of the Rheumatic Diseases
Ab0145 Effects of Immunosuppressive Medication on Type I Interferon Activation: in Vitro Analysis Shows a Downregulating Effect on Ifn Activation of Hydroxychloroquine and Aspirin
2020 · M.J. Wahadat, M. Lourens, et al. · Annals of the Rheumatic Diseases
PDF
Sat0661 Mxa Is a Clinically Applicable Biomarker for Type I Interferon Activation in Systemic Lupus Erythematosus and Systemic Sclerosis
2019 · Erika Huijser, C.G. van Helden-Meeuwsen, et al. · Annals of the Rheumatic Diseases
PDF
Works count: 24
Citation count: 254
H-index: 9
I10-index: 9
Year
Topic
Type